Past Investments

terumoAmnion, Inc.

Acquired by Gambro BCT; Name changed to CaridianBCT July 14, 2008; CaridianBCT aquired by Terumo March 2011.
Tokyo Stock Exchange: 4543

agenusAntigenics, Inc.

Antigenics acquired Aronex Pharmaceuticals in 2001; Name change to Agenus Jan 2011.

biomerieuxBacterial Barcodes

Acquired by bioMérieux, Inc. in 2006.
NYSE Euronext: BIM

forumForum Pharmaceuticals

Formerly EnVivo Pharmaceuticals.

Genosys Biotechnologies, Inc.

Acquired by Sigma-Aldrich in 1998.

larkLark Technologies, Inc.

Acquired by Genaissance Pharmaceuticals in 2004; Genaissance Pharmaceuticals acquired by Clinical Data Inc. in October 2005; Clinical Data Inc. Acquired by Forest Laboratories in 2011.
NYSE Euronext: FRX

lexiconLexicon Pharmaceuticals, Inc.


medical metricsMedical Metrics

Meretek Diagnostics, Inc.

Subsidiary of Otsuka America.


Formally MithraTech.

Oncovance Technologies

GE healthcarePrimaCIS Health information Technology, Inc.

PrimaCIS was acquired by MedicaLogic in 1999; acquired by GE Medical Systems April 1, 2002.
NYSE Euronext: GE

reprosRepros Therapeutics Inc.

Formerly Zonagen, Inc.

Sapphire TherapeuticsSapphire Therapeutics

Sapphire is a biopharmaceutical company committed to developing and commercializing promising compounds that are ready for clinical or pre-clinical testing in oncologic and metabolic disease. The most advanced drug candidate in Sapphire’s pipeline is a small molecule ghrelin agonist. Switzerland-based pharmaceutical group Helsinn has acquired the US-based biopharmaceutical company, Sapphire Therapeutics. Phase II human clinical trials for cancer cachexia.


Acquired by SkillSoft in 2002.

Perkin ElmerSpectral Genomics

Acquired by PerkinElmer, Inc. in 2006.
NYSE Euronext: PKI

valentisValentis, Inc.

Formerly GeneMedicine, Inc.; merged with Megabios in 1999 and became Valentis.

Invovio VGX Pharmaceuticals

Formerly ADViSYS; acquired by Inovio Biomedical Corporation in 2009.
NYSE Euronext: INO